Litcius/Paper detail

A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Vincent Ribrag, Seung‐Tae Lee, David A. Rizzieri, Martin J.S. Dyer, Luis Fayad, Razelle Kurzrock, Leslie A. Andritsos, Réda Bouabdallah, Amjad Hayat, Larry Bacon, Yu Jiang, Kowser Miah, Bruno Delafont, Oday Hamid, S. Anyanwu, Pablo Martínez, Brian Hess

2020Clinical Lymphoma Myeloma & Leukemia28 citationsDOI

Topics & Concepts

DurvalumabMedicineTremelimumabRefractory (planetary science)OncologyInternal medicinePhases of clinical researchDiffuse large B-cell lymphomaLymphomaClinical trialImmunotherapyCancerNivolumabIpilimumabAstrobiologyPhysicsLymphoma Diagnosis and TreatmentCAR-T cell therapy researchCutaneous lymphoproliferative disorders research
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Litcius